News & Events zu 10X Genomics Inc (TXG)TXG10X Genomics Inc

10x Genomics Awarded $4.8M for Parse Biosciences Infringement

10x Genomics (TXG) announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025. The patents are exclusively licensed from Roche Sequencing Solutions. The jury also rejected Parse's challenges to the validity of the patents, finding all three patents valid and enforceable. "The jury awarded 10x over $4.8M in damages for sales of Parse's infringing Evercode Whole Transcriptome products from February 2021 through June 30, 2026. The damages award is based on a 14% royalty rate on infringing Parse sales. In post-trial proceedings, 10x will seek additional awards including enhanced damages and attorneys' fees for Parse's willful infringement, and a permanent injunction stopping further infringement by Parse in the United States," the company stated. "The evidence presented at trial shows that Parse made a deliberate and calculated decision to ignore Dr. Nolan's seminal inventions in single cell analysis. The jury heard the evidence and soundly rejected Parse's defenses to find that Parse willfully infringed the patents exclusively licensed to Scale. We are pleased with today's verdict, which makes clear that companies cannot simply benefit from the innovation of others and disregard the patent rights protecting them," said Randy Wu, General Counsel of 10x Genomics.

Stock Futures Mixed as Doximity Soars 83.93%

Stock futures were mixed following a mostly lower regular session as investors continue to digest another round of corporate earnings and await news out of the Middle East.Economic data remains a central focus ahead of Friday's July employment report. Markets remain divided over the Federal Reserve's next policy move, with incoming employment data expected to play an important role in shaping expectations for interest rates over the coming months.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Doximityup 83.93%Atlassianup 32.1%Figsup 24.6%QuinStreetup 23%Cloudflareup 16.9%Twilioup 16.7%Nateraup 15.3%Akamaiup 13%Airbnbup 10.3%Instacartup 9%ALSO HIGHER -DoubleVerifyup 13.2% after Nielsen agreed to acquire the company in an all-cash transaction valued at roughly $2.15BDOWN AFTER EARNINGS -Trade Deskdown 24.5%QuidelOrthodown 21.8%Xponential Fitnessdown 12.9%Cable Onedown 9.5%Maravai Lifesciencesdown 8.8%ResMeddown 5.9%10x Genomicsdown 4.7%Dropboxdown 4.1%Post Holdingsdown 3%

10x Genomics Partners with Lausanne University Hospital to Advance Cancer Diagnostics Research

10x Genomics announced a research collaboration with Lausanne University Hospital, or CHUV, one of Switzerland's leading academic medical centers, to advance research in diagnostic applications of single cell and spatial technologies for cancer care. This collaboration builds on 10x's broader efforts to work with leading research institutions to generate the scientific evidence needed to advance future diagnostic applications of single cell and spatial technologies. Through this multi-year collaboration, the study intends to use 10x's Flex Apex and Xenium platforms, with the goal of expanding to the Atera platform, to examine tumor samples from patients with advanced cancer undergoing a comprehensive evaluation by a clinical molecular tumor board. The research aims to identify clinically relevant biomarkers that may help predict treatment response, cancer prognosis and support diagnostic development. The study is expected to include hundreds of patients across multiple solid tumor types, including non-small cell lung cancer, breast cancer, bladder cancer and melanoma. Researchers plan to integrate single cell and spatial biology with clinical outcomes data to better understand mechanisms of response and resistance across a range of therapeutic approaches, including antibody-drug conjugates, bispecific antibodies and immune checkpoint inhibitors. The collaboration also intends to investigate how 10x single cell and spatial technologies can be deployed clinically alongside current standard-of-care assays.